Zobrazeno 1 - 10
of 39 839
pro vyhledávání: '"kras"'
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1019-1024 (2024)
Introduction: Pulmonary sarcomatoid carcinomas (PSCs) are a rare subgroup of non-small cell lung cancer (NSCLC). In contrast to other NSCLCs, PSCs have a poor prognosis due to limited efficacy of radiation and chemotherapy. Therefore, other therapeut
Externí odkaz:
https://doaj.org/article/e9aeacf3b12541dba69d6d6178168d3b
Publikováno v:
Big Data Mining and Analytics, Vol 7, Iss 3, Pp 590-602 (2024)
Kirsten rat sarcoma viral oncogene homolog (namely KRAS) is a key biomarker for prognostic analysis and targeted therapy of colorectal cancer. Recently, the advancement of machine learning, especially deep learning, has greatly promoted the developme
Externí odkaz:
https://doaj.org/article/e5318c9013be456dab7a3a654e626975
Autor:
Akinari Tsukada, Chie Morita, Yosuke Shimizu, Yukari Uemura, Go Naka, Jin Takasaki, Hiroshi Nokihara, Shinyu Izumi, Masayuki Hojo
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1854-1862 (2024)
Abstract Background Recent advancements in advanced non‐small‐cell lung cancer (NSCLC) treatment have significantly improved primary therapy outcomes owing to the emergence of various molecular targeted therapies and immune checkpoint inhibitors
Externí odkaz:
https://doaj.org/article/e9686ee606c04e7b85e9be9001db83ce
Publikováno v:
OncoTargets and Therapy, Vol Volume 17, Pp 683-695 (2024)
Min Tang,1,2 Yijun Wu,1,2 Xiufeng Bai,3,4 You Lu1,2 1Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Lab
Externí odkaz:
https://doaj.org/article/da8e97a3aa054698abc754b33185ddd5
Autor:
Javiera Garrido, Yanara Bernal, Evelin González, Alejandro Blanco, Gonzalo Sepúlveda-Hermosilla, Matías Freire, Karen Oróstica, Solange Rivas, Katherine Marcelain, Gareth Owen, Carolina Ibañez, Alejandro Corvalan, Marcelo Garrido, Rodrigo Assar, Rodrigo Lizana, Javier Cáceres-Molina, Diego Ampuero, Liliana Ramos, Paola Pérez, Osvaldo Aren, Sara Chernilo, Cristina Fernández, María Loreto Spencer, Jacqueline Flores Aguila, Giuliano Bernal Dossetto, Mónica Ahumada Olea, Germán Rasse, Carolina Sánchez, Maria Galli de Amorim, Thais F. Bartelli, Diana Noronha Nunes, Emmanuel Dias-Neto, Helano C. Freitas, Ricardo Armisén
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Tobacco use is one of the main risk factors for Lung Cancer (LC) development. However, about 10–20% of those diagnosed with the disease are never-smokers. For Non-Small Cell Lung Cancer (NSCLC) there are clear differences in bot
Externí odkaz:
https://doaj.org/article/299f116c68364c9a8cb95e5dde0ba0e8
Publikováno v:
Медицинская иммунология, Vol 26, Iss 4, Pp 835-842 (2024)
Cytokines and chemokines play dual – pro- and antioncogenic – roles in tumor progression. Targeted medications of monoclonal antibodies, anti-VEGF (bevacizumab) and anti-EGFR (cetuximab, panitumumab), are widely used in treatment of metastatic co
Externí odkaz:
https://doaj.org/article/67efbeb59b78490896e4fbc457fd6cce
Autor:
Alexander Siegman, Aaron Shaykevich, Danbee Chae, Isaac Silverman, Sanjay Goel, Radhashree Maitra
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 7, Pp 7530-7547 (2024)
The KRAS gene is mutated in approximately 45% of colorectal cancer patients. There are currently very few targeted treatments or therapies equipped to directly inhibit KRAS due to its unusual structural intricacies. Erlotinib, an EGFR inhibitor, has
Externí odkaz:
https://doaj.org/article/08004cdcbccf45a08d50130a8c2da875
Autor:
Hiroshi Kotani, Hiroko Oshima, Justin C. Boucher, Tomoyoshi Yamano, Hiroyuki Sakaguchi, Shigeki Sato, Koji Fukuda, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Takumi Nishiuchi, Masanobu Oshima, Marco L. Davila, Seiji Yano
Publikováno v:
Journal of Biomedical Science, Vol 31, Iss 1, Pp 1-13 (2024)
Abstract Background KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRAS G12C inhibitors have recently been approved, effective precision therapies
Externí odkaz:
https://doaj.org/article/e76a3f8454924a68ab32ec86f27f0f26
Autor:
Praveen Guruvaiah, Romi Gupta
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Oncogenic mutations in the RAS gene are associated with uncontrolled cell growth, a hallmark feature contributing to tumorigenesis. While diverse therapeutic strategies have been diligently applied to treat RAS-mutant cancers, suc
Externí odkaz:
https://doaj.org/article/ad4809f736484197a181c829b8bf3a50